TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05127681

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry
Description: A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: medical data collection
Description: Data of healthy men is already available
Study: NCT05318495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD-EYE
Description: CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD-EYE
Description: CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE
Description: The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE
Description: The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
Study: NCT06371157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: AK104
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TACE
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE
Description: TACE (chemo and embolic agent injection into the hepatic artery)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AK104
Description: intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Lenvatinib
Description: oral

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo for Lenvatinib
Description: oral
Study: NCT06287021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jump System Traser® cup
Description: Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jump System HAX-Pore® cup
Description: Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
Study: NCT06213207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator based training to manage asphyxia and essential newborn care using neonatalie
Description: The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
Study: NCT04514731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
Study: NCT04951219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resmetirom
Description: Tablet
Study: NCT05782985

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Description: Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Description: Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
Study: NCT05343585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PortionSize AI
Description: For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
Study: NCT05446623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanil
Description: The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
Study: NCT04859101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: 2 minutes of gum chewing prior to procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 2 swallows prior to procedure
Study: NCT06007508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Long-acting insulin
Study: NCT05906992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P53
Description: Intravenous(IV) infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Ocrevus
Description: Intravenous(IV) infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Ocrevus
Description: Intravenous(IV) infusion
Study: NCT06056206

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Revascularisation procedures will be performed according to randomised list.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Revascularisation procedures will be performed according to randomised list.
Study: NCT06457113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional Attention Bias Modification
Description: These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
Study: NCT04799002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan intraocular injection for chemotherapy in retinoblastoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan intraocular injection for chemotherapy in retinoblastoma
Study: NCT06295380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual environment practiced on the Caren
Description: The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy
Study: NCT05882760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetric N Bond Universal®
Description: Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self Etch Tetric N Bond Universal®
Description: Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GC Fuji IX, GC, Japan®
Description: Cavities will be restored with GC Fuji IX, GC, Japan®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activa TM Bioactive Restorative ®
Description: Cavities will be restored with Activa TM Bioactive Restorative ®
Study: NCT04922853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capox chemotherapy
Description: oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals

Intervention type: DRUG
Group type: OTHER
Intervention: Capox chemotherapy
Description: oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
Study: NCT05230511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus RhamnosusGG
Description: LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus RhamnosusGG
Description: LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline bladder wash
Description: Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline bladder wash
Description: Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
Study: NCT06453382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural change modification, Screening, NCD related knowledge practice and attitude
Description: The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
Study: NCT05545592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low oestrogen dosage
Description: From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
Study: NCT06149923

Intervention type: GENETIC
Intervention: quantitative Real-time PCR
Description: : quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
Study: NCT05897073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating intervention
Description: Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
Study: NCT05516160

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic of optical aberrations
Description: diagnostic of optical aberrations with new device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnostic of optical aberrations
Description: diagnostic of optical aberrations with new device
Study: NCT05897073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating plus exercise intervention
Description: Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
Study: NCT06059612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection
Description: steroid injection into superior cluneal nerve
Study: NCT05186987

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study: NCT06387030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Esophageal biopsies
Description: 4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unstimulated saliva sampling
Description: A esophageal brushing will be done during digestive endoscopy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: A urine sample will be collected during hospitalization for digestive endoscopy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool sampling
Description: A stool sample will be collected during hospitalization for digestive endoscopy.
Study: NCT05153447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-Tech
Description: M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomized to the usual care arm will receive standard of care.
Study: NCT04991272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prewarming and warmed fluid infusion
Description: prewarming with forced air warming system and warmed fluid infusion.
Study: NCT05408117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Polypropylene epidermal suture
Description: Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Polypropylene epidermal suture
Description: Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Fast gut epidermal suture
Description: Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Fast gut epidermal suture
Description: Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture